INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.970
-0.040 (-1.99%)
At close: Sep 15, 2025, 4:00 PM EDT
2.000
+0.030 (1.52%)
Pre-market: Sep 16, 2025, 7:48 AM EDT
INmune Bio Market Cap
INmune Bio has a market cap or net worth of $52.37 million as of September 16, 2025. Its market cap has decreased by -62.46% in one year.
Market Cap
52.37M
Enterprise Value
19.45M
1-Year Change
-62.46%
Ranking
Category
Stock Price
$1.97
Market Cap Chart
Since February 4, 2019, INmune Bio's market cap has decreased from $77.82M to $52.37M, a decrease of -32.70%. That is a compound annual growth rate of -5.82%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 12, 2025 | 53.44M | -48.39% |
| Dec 31, 2024 | 103.55M | -48.97% |
| Dec 29, 2023 | 202.92M | 78.35% |
| Dec 30, 2022 | 113.78M | -37.49% |
| Dec 31, 2021 | 182.00M | -21.41% |
| Dec 31, 2020 | 231.57M | 270.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Feb 4, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 671.68B |
| Johnson & Johnson | 427.24B |
| AbbVie | 384.42B |
| UnitedHealth Group | 315.07B |
| Novo Nordisk | 248.69B |
| AstraZeneca | 240.71B |
| Novartis AG | 238.00B |
| Abbott Laboratories | 228.57B |